Enanta Pharmaceuticals Inc (ENTA) stock
ENTANasdaqPharmaceutical PreparationsFiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026Score 2/3018% above fair value
$10.99−0.21 (-1.87%)
Close on Nov 13, 2026Market cap $320.09MP/E –Yield –
Enanta Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Enanta Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $86.24M. For fiscal 2025 it was $106.74M, down 18.8% from the year before. Over ten years it grew 16.5% a year on average. The highest annual figure on record is $174.11M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $106.74M | -18.8% |
| FY2024 | Sep 30, 2024 | $131.48M | -19.6% |
| FY2023 | Sep 30, 2023 | $163.52M | -0.6% |
| FY2022 | Sep 30, 2022 | $164.52M | -5.5% |
| FY2021 | Sep 30, 2021 | $174.11M | +27.3% |
| FY2020 | Sep 30, 2020 | $136.76M | -3.8% |
| FY2019 | Sep 30, 2019 | $142.21M | +49.9% |
| FY2018 | Sep 30, 2018 | $94.86M | +65.1% |
| FY2017 | Sep 30, 2017 | $57.45M | +42.0% |
| FY2016 | Sep 30, 2016 | $40.46M | +74.5% |
| FY2015 | Sep 30, 2015 | $23.19M | +23.7% |
| FY2014 | Sep 30, 2014 | $18.74M | +11.3% |
| FY2013 | Sep 30, 2013 | $16.84M | +11.4% |
| FY2012 | Sep 30, 2012 | $15.12M | +30.9% |
| FY2011 | Sep 30, 2011 | $11.55M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | $22.13M | -20.0% |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | $19.44M | -36.8% |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | $20.86M | -27.4% |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | $23.81M | -33.1% |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | $27.66M | -24.0% |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | $30.78M | -14.9% |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | $28.74M | -33.1% |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | $35.59M | -18.1% |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | $36.37M | -11.1% |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | $36.17M | +3.9% |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | $42.99M | +10.0% |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | $43.47M | +3.3% |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | $40.90M | -15.8% |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | $34.80M | -28.9% |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | $39.09M | -16.8% |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | $42.09M | +1.4% |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | $48.55M | +32.4% |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | $48.95M | +33.4% |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | $46.99M | +35.5% |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | $41.51M | +27.3% |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | $36.67M | +11.9% |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | $36.69M | -5.3% |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | $34.68M | +0.6% |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | $32.61M | -4.5% |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | $32.78M | -6.0% |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | $38.72M | +43.8% |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | $34.46M | +21.0% |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | $34.16M | +59.0% |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | $34.88M | +94.2% |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | $26.92M | +63.0% |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | $28.49M | +84.9% |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | $21.48M | +65.2% |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | $17.96M | +43.4% |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | $16.51M | +43.6% |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | $15.41M | +42.9% |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | $13.00M | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | $12.53M | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | $11.50M | – |
| Q3 FY2016CQ2 2016 | Jun 30, 2016 | $10.79M | – |
See a number that looks wrong?